عنوان الدراسة | الجهاز | رقم البروتوكول | الراعي | الحالة | موقع الدراسة |
---|---|---|---|---|---|
"A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled |
LPS15396 |
SANOFI |
جاري | Sultan bin Abdulaziz Humanitarian city (Riyadh) | |
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, | 105MS306 |
Biogen |
جاري | King Faisal Specialist Hospital and Research Center (Jeddah) | |
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical T | S1007 |
King Faisal Specialist Hospital & Research Center |
جاري | King Faisal Specialist Hospital and Research Center (Riyadh) | |
"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Tripl |
D3614C00001 |
AstraZeneca |
جاري | King Fahad Specialist Hospital (Dammam) | |
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Pre | D8221C00001 |
Acerta Pharma BV | جاري | King Fahad Specialist Hospital (Dammam) | |
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Ne | I3Y-MC-JPCF | Eli Lilly | جاري | King Fahad Medical City (Riyadh) | |
"A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED |
MO39196 | Roche |
جاري | International Medical Center (Jeddah) | |
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in | 19-2017 |
MEDIS Laboratories |
جاري | Saudi Ajal | |
ATOS study_A 12–month prospective observational study assessing the real-world clinical effectiveness, safety and health-economic benefits of Toujeo® initiation after oral antidiabetic drug failure in insulin-naïve patients with type 2 diabetes melli | OBS14708 |
SANOFI |
جاري | King Abdulaziz University Hospital (Jeddah) | |
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy | 21-2017 v.02 | MEDIS Laboratories | جاري | Saudi Ajal |